Mallinckrodt Plc Ordinary Share (MNK) 122.95

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 11:41 PM

Mallinckrodt Plc Ordinary Share (MNK) 122.95 $MNK

Mallinckrodt To Present At Deutsche Bank Healthcare Conference
PR Newswire - Wed Apr 22, 4:00PM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, will present on Wednesday, May 6, 2015, at the Deutsche Bank 40th Annual Health Care Conference at the InterContinental Boston hotel in Boston, Mass.
MNK: 122.95 (-2.22), DB: 33.95 (+0.61)

Akorn Leads Top Generic-Drug Stocks, Nears Buy Point
at Investor's Business Daily - Mon Apr 20, 5:06PM CDT
The generic-drug group was ranked No. 2 out of the 197 industries tracked by IBD on Monday, so it's little wonder that three of its members made the 16-stock Spotlight screen. Akorn (AKRX), arguably the top stock in the industry, is nearing a 55.96...
MNK: 122.95 (-2.22), LCI: 66.45 (-0.28), AKRX: 53.70 (-1.69)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 4:36PM CDT

MNK: 122.95 (-2.22), FARO: 44.64 (-0.93), MDVN: 128.88 (+0.29), CRIS: 2.88 (+0.09), E: 36.62 (+0.43), PH: 123.47 (+1.33), YOKU: 16.42 (-0.21), FXCM: 2.13 (+0.02), VSLR: 14.33 (+0.36), IGT: 19.88 (-0.02)

Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:10PM CDT
Novartis AG (NVS) announced that its generic arm has received FDA approval for Glatopa, the first generic version of Teva Pharmaceuticals' (TEVA) multiple sclerosis drug, Copaxone.
MNK: 122.95 (-2.22), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)

Pacira Down on Subpoena on Exparel Marketing Issues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 3:10PM CDT
Shares of Pacira Pharmaceuticals, Inc. (PCRX) were down 9.6% after the company received a subpoena from the U.S. Department of Justice, U.S. Attorney's Office for the District of New Jersey.
MNK: 122.95 (-2.22), VRX: 206.93 (-3.92), ARQL: 2.11 (-0.03), PCRX: 83.61 (-0.41)

Mallinckrodt completes Ikaria buy
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 7:11AM CDT

MNK: 122.95 (-2.22)

Mallinckrodt acquires Ikaria for about USD2.3bn in cash
M2 - Fri Apr 17, 6:10AM CDT
Biopharmaceutical company Mallinckrodt (NYSE:MNK) revealed on Thursday that it has completed the acquisition of Ikaria for a purchase price of about USD2.3bn in all-cash transaction.
MNK: 122.95 (-2.22)

Mallinckrodt Completes Acquisition Of Ikaria
PR Newswire - Thu Apr 16, 3:15PM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today announced that it has completed its acquisition of Ikaria, Inc. at a purchase price of approximately $2.3 billion. The Ikaria acquisition extends Mallinckrodt's footprint in the hospital market and expands its reach into neonatal critical care with INOMAX® (inhaled nitric oxide), a vital treatment option for a highly vulnerable patient population. It also accelerates Mallinckrodt's rapid growth in specialty brands -- adding significant portfolio diversity with a high-value, high-margin integrated drug-device-service product offering.
MNK: 122.95 (-2.22)

Roche Collaborates with Astellas Pharma for Tissue Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:22PM CDT
Roche Holding Ag (RHHBY) announced that its member company, Ventana Medical Systems, Inc. has entered into a master collaboration agreement with Japan-based Astellas Pharma Inc. (ALPMY).
MNK: 122.95 (-2.22), VRX: 206.93 (-3.92)

Abbott Labs, Sekisui Medical to Offer Coagulation Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:06PM CDT
Abbott Laboratories (ABT) announced that it has entered into an agreement with Sekisui Medical to offer coagulation testing solutions for laboratories on a worldwide basis.
MNK: 122.95 (-2.22), ABT: 48.35 (+1.23), VRX: 206.93 (-3.92), ABBV: 64.52 (+0.91)

Mallinckrodt Pharmaceuticals to Sponsor the National Kidney Foundation Kidney Walk
GlobeNewswire - Tue Apr 14, 3:00PM CDT
Mallinckrodt Pharmaceuticals (NYSE:MNK) has been named National Corporate Sponsor for the 2015 Kidney Walk and will sponsor 100 Kidney Walk events in major U.S. cities as part of its support of the National Kidney Foundation (NKF).
MNK: 122.95 (-2.22)

Roche Acquires CAPP Medical to Strengthen Cancer Diagnosis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 1:37PM CDT
Roche Holding AG (RHHBY) announced that it has acquired privately-held genomics research company, CAPP Medical.
MNK: 122.95 (-2.22), VRX: 206.93 (-3.92), ARQL: 2.11 (-0.03)

Pacira Announces Encouraging Data on Lead Drug Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:11PM CDT
Pacira Pharmaceuticals Inc. (PCRX) announced encouraging new data from a study conducted on its lead drug Exparel by the University Of Illinois College Of Medicine.
MNK: 122.95 (-2.22), VRX: 206.93 (-3.92), ARQL: 2.11 (-0.03), PCRX: 83.61 (-0.41)

Casey's General Store, MercadoLibre, Valero Energy, Mallinckrodt and Marathon Petroleum highlighted as Zacks Bull and Bear of the Day - Press Releases
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 8:30AM CDT
Casey's General Store, MercadoLibre, Valero Energy, Mallinckrodt and Marathon Petroleum highlighted as Zacks Bull and Bear of the Day
MNK: 122.95 (-2.22), VLO: 59.35 (+1.02), MPC: 102.13 (+2.12), MELI: 138.04 (+1.09), CASY: 86.46 (-0.97)

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace
at The Street - Fri Apr 10, 6:15AM CDT
The recent bid by Mylan to acquire Perrigo offers the latest example of pharma companies that have been seeking growth opportunities.
MNK: 122.95 (-2.22), AGN: 240.22 (+2.88), VRX: 206.93 (-3.92), PRGO: 201.50 (+8.68), ACT: 295.22 (+0.69), COV: 106.71 (-1.36), SLXP: 172.96 (+0.15), HZNP: 30.96 (+0.10), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Jim Cramer's 'Mad Money' Recap: Ignore the Chatter, Stick With Best-of-Breed Stocks
at The Street - Thu Apr 09, 7:28PM CDT
Many investors are getting caught up in the takeover speculation game, Cramer warns. Don't do it.
MNK: 122.95 (-2.22), VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), GE: 26.91 (+0.29), TERP: 42.15 (+0.47), SPG: 189.11 (+0.28), IMGN: 9.96 (+0.01), MYL: 72.40 (-1.67), MO: 52.12 (+0.02), VTR: 72.71 (-0.08), RAD: 8.32 (+0.39), SBUX: 48.33 (-0.04), UA: 82.27 (-1.25), T: 32.86 (+0.20), PM: 83.69 (-0.36), AA: 13.57 (+0.05), RIG: 16.85 (-0.18), SUNE: 27.27 (+0.56), HZNP: 30.96 (+0.10), AAL: 51.40 (+0.04), COST: 146.98 (-0.36), TWTR: 51.73 (+0.41), MAC: 83.25 (+0.65), WTW: 7.81 (+0.16)

3 Top-Ranked Stocks Likely to Beat Earnings This Quarter - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 3:36PM CDT
Use the Zacks' Earnings ESP system to discover the winners of this earnings season before they report.
MNK: 122.95 (-2.22), VLO: 59.35 (+1.02), MPC: 102.13 (+2.12)

Actavis and Rhythm Start Mid-Stage Study on Relamorelin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 9:40AM CDT
Actavis (ACT) and Rhythm announced the initiation of a phase IIb study on relamorelin.
MNK: 122.95 (-2.22), ACT: 295.22 (+0.69), IRWD: 15.07 (-0.19), AKRX: 53.70 (-1.69)

Mylan makes $205/share bid for Perrigo; Generic firms rally
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 10:47AM CDT

IPXL: 49.58 (-0.40), MNK: 122.95 (-2.22), LCI: 66.45 (-0.28), PRGO: 201.50 (+8.68), TARO: 143.40 (-0.31), AKRX: 53.70 (-1.69), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Mallinckrodt to offer USD1.2bn notes
M2 - Tue Apr 07, 6:47AM CDT
Biopharmaceutical company Mallinckrodt (NYSE:MNK) said on Monday that it plans to issue USD1.2bn of US dollar-denominated senior unsecured notes due 2020 and 2025.
MNK: 122.95 (-2.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A Shot at Adventure Without Opening Your Wallet Let me tell you, Korea's got a way of sweeping folks off their feet with a little something for everyone—from a foodie’s paradise to history buff heaven. The Korea Tourism Organization's (KTO) New York Office is lighting up the stage with a slick offer: enter a quiz on their website and you might just be jetting off to...

Strategic Move: Chimney Collective Teams with Four Winds

A Partnership Fueled by Legacy and Growth In the world of brick, mortar, and flue, a big play just unfolded. Chimney Collective, flexing its investment muscle, has hitched its wagon to Four Winds Chimney, a company that's carved out quite a niche in New York's chimney scene. We're not talking about a corporate takeover here; this is about putting money where growth and...

Zenni and Chase Stokes Foster Student Wellbeing in NYC

Picture this: near 300 high schoolers milling around, glancing through shiny new glasses from the Zenni x Chase Stokes collection. In the heart of New York City, these kids are getting a double-dose of care that's all too rare—free vision screenings paired with mental health support. It's the kind of collaboration that shows you what's possible when a company, an actor,...

TKO's Bold $2B All-Cash Move for SVC's Hotels

TKO's Big, Bold Bid: What Does it Mean? In the crazy world of high-stakes hospitality investments, there are moments that turn heads. TKO's $2 billion all-cash offer to snag Service Properties Trust's prized hotel portfolio is exactly one of those shake-ups. Let's not sugarcoat it; this is a bold move to the big leagues, and it's not without its quirks. A Cash-Infused...

Boliden's Q3 2026 Results: What's on the Horizon?

Boliden Ready to Reveal Q3 Numbers Mark it down, folks. Thursday, October 29, 2026, is the day when Boliden's big wigs will step up to the plate and lay their cards on the table about the company's performance over the last quarter. If you've got any skin in this mining powerhouse, you'll want a front-row seat—or at least a virtual one if you're dialing in from...

Icebox Takes on Buckhead with Diamonds and Discounts

So, Atlanta's Icebox Diamonds & Watches just dropped a news bomb that could shake up anyone with a taste for glitz and a wallet ready to act. This iconic jeweler, swinging its roots from a humble family biz to a global gem, is opening up its vault with an Inventory Reduction Sale starting October 9. And folks, it’s happening right at their Buckhead flagship showroom....

AI Visibility: A Game Changer for SEO in 2027?

AI Changes the SEO Game Rank Math, the brains behind a trusty WordPress SEO plugin, has thrown a bold prediction at us: AI visibility is set to become a standard SEO metric next year. Gurugram, India, saw this gem of an announcement on October 9, 2026. So, what's ticking here? Consumers, more than ever, are resting on AI-generated answers to make decisions. It's like...

Toyland 2026: Blain's 'Open The Magic' Event Marks 69 Years

There's something about nostalgia that hooks you right in the gut, like remembering those jittery walks through Blain's Farm & Fleet's Toyland aisles. If there's one thing these folks know, it's how to spark holiday cheer deep in the Midwest bones. Here we are, just before the dust settles on another year, and Blain's is rolling out its 69th Toyland party—a cherished...

Morphe’s Auction Hits High Notes with Fine Jewelry

Luxurious Gems Steal the Spotlight When the gavel dropped at Morphy's Fine Jewelry & Watches Auction, it set the stage for a spectacular showcase of opulent treasures. The event, highlighting 632 lots and tallying over $1.8 million in sales, left bidders buzzing in anticipation of their next chance to snag a slice of elegance. Bvlgari's Serpentine Charm In the spotlight...

Caitlyn Brazill Takes Helm at Per Scholas: CEO Transition

Caitlyn Brazill named CEO, marking a leadership shift Call this one a big baton pass in the world of workforce development. Caitlyn Brazill is stepping into the role of CEO and President at Per Scholas, effective January 1, 2027. She'll be filling the rather large shoes of Plinio Ayala, the man who's been steering the ship since its days in the Bronx, growing it into a...